Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875482 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 157
- Enrollment target
NCT03875482 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 157 participants.
The verdict
NCT03875482, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 157 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
Interventions
- DRUG Risankizumab
- DRUG Placebo solution for risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03875482
The ClinicalTrials.gov registry entry for NCT03875482 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risankizumab is the first listed.
NCT03875482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03875482 about?
NCT03875482 is a clinical study titled "A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis". The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT03875482?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 157 participants. The study started on 2019-05-13. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03875482?
The interventions under investigation include: Risankizumab (DRUG), Placebo solution for risankizumab (DRUG).
Who is sponsoring clinical trial NCT03875482?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.